Bioactivity of Three Salvia Species in Relation to Their Total Phenolic and Flavonoid Contents
- Autores: Sharopov F.1,2, Valiev A.2, Sobeh M.1, Arnold E.1, Winka M.1
- 
							Afiliações: 
							- Institute of Pharmacy and Molecular Biotechnology, Heidelberg University
- Department of Pharmaceutical Technology, Avicenna Tajik State Medical University
 
- Edição: Volume 52, Nº 7 (2018)
- Páginas: 596-600
- Seção: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245362
- DOI: https://doi.org/10.1007/s11094-018-1866-6
- ID: 245362
Citar
Resumo
Antioxidant, anti-inflammatory, cytotoxic activities and total phenolic and flavonoid contents of methanol extracts of three Salvia species including Salvia discolor, S. officinalis and S. sclarea were investigated. The compositions of extracts were analyzed by high performance liquid chromatography (HPLC) with a UV-DAD detector. The major component of extracts from aerial parts of Salvia species was rosmarinic acid (0.2 – 61.1%). The composition of methanol extract from aerial parts strongly differed from that of the root extract. The total phenolic and flavonoid contents per 100 g fresh weight ranged within 658.3 – 1805.9 mg of caffeic acid equivalent (CAE) and 13.0 – 184.9 mg of quercetin equivalent (QE), respectively. The highest DPPH• radical scavenging effect was observed for S. sclarea extract (with an IC50 of 21.6 μg/mL), while S. discolour extract exhibited the highest ABTS•+ radical scavenging ability (with IC50 of 53.0 μg/mL) among all extracts. All Salvia extracts showed remarkable cytotoxic effect toward human T-lymphoblast leukemia (CCRF-CEM) and adriamycin resistant leukemia (CEM/ADR 5000) with average IC50 values of 25.3 – 65 μg/mL and 34.5 – 89.8 μg/mL, respectively. A relatively strong effect against human breast adenocarcinoma (MCF-7) was observed for the S. officinalis extract, with an IC50 of 138.5 μg/mL.
Palavras-chave
Sobre autores
Farukh Sharopov
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University; Department of Pharmaceutical Technology, Avicenna Tajik State Medical University
							Autor responsável pela correspondência
							Email: shfarukh@mail.ru
				                					                																			                												                	Alemanha, 							Im Neuenheimer Feld 364, Heidelberg, D-69120; Rudaki 139, Dushanbe, 734003						
Abdujabbor Valiev
Department of Pharmaceutical Technology, Avicenna Tajik State Medical University
														Email: wink@uni-hd.de
				                					                																			                												                	Tajiquistão, 							Rudaki 139, Dushanbe, 734003						
Mansour Sobeh
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University
														Email: wink@uni-hd.de
				                					                																			                												                	Alemanha, 							Im Neuenheimer Feld 364, Heidelberg, D-69120						
Eva Arnold
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University
														Email: wink@uni-hd.de
				                					                																			                												                	Alemanha, 							Im Neuenheimer Feld 364, Heidelberg, D-69120						
Michael Winka
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University
							Autor responsável pela correspondência
							Email: wink@uni-hd.de
				                					                																			                												                	Alemanha, 							Im Neuenheimer Feld 364, Heidelberg, D-69120						
Arquivos suplementares
 
				
			 
						 
						 
						 
						 
					 
				 
  
  
  
  
  Enviar artigo por via de e-mail
			Enviar artigo por via de e-mail  Acesso aberto
		                                Acesso aberto Acesso está concedido
						Acesso está concedido Somente assinantes
		                                		                                        Somente assinantes
		                                					